ROCKAWAY, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will present at the 13th Annual LD Micro Invitational XIII in Los Angeles, California from June 6-8, 2023.
LD Micro Invitational XIII:
Date: Tuesday, June 6, 2023
Time: 11:00 AM PT
Event: Presentation
Virtual viewers: Livestream
For more information regarding the Invitational and to register to watch the presentation live, please visit the conference page here.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Investors:
Rich Cockrell
CG Capital
404-736-3838
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$16.54 |
Daily Change: | -0.36 -2.13 |
Daily Volume: | 120,469 |
Market Cap: | US$108.340M |
January 07, 2025 November 13, 2024 September 10, 2024 August 07, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load